+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nasal Polyps Treatment Market by Type of Treatment, Route of Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • ID: 5480783
  • Report
  • September 2021
  • Region: Global
  • 256 Pages
  • Allied Analytics LLP
The global nasal polyps treatment market was valued at $2,482.7 million in 2020 and is projected to reach $4,243.9 million by 2030 registering a CAGR of 5.60% from 2021 to 2030.



Nasal polyps are a chronic inflammatory condition of nose and paranasal sinuses. They are characterized by slow, progressive nasal obstruction, with accompanied reduction in sense of smell. Polyps appear generally pale (yellow-grey color) and insensate, while turbinates are pink/reddish and feel light to touch. At least every third patient with nasal polyps have asthma. Symptoms associated with nasal polyps include trouble breathing through nose, loss of smell, decreased taste, post nasal drip, and a runny nose. The growths are sac-like, movable, and nontender, though face pain may occasionally occur. In addition, complications may include sinusitis and broadening of nose. Nasal polyps treatment such as oral and nasal medications are used to shrink or eliminate nasal polyps.

The main factors that drive growth of the nasal polyps treatment market include increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP), along with rise in geriatric population, which are more vulnerable for development of chronic rhinosinusitis with nasal polyps. In addition, rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons and huge product pipeline of nasal polyps treatment with growth in research activities further boost growth of the nasal polyps treatment market. However, high cost and complications associated with sinus surgeries such as excessive bleeding, cerebrospinal fluid leak, visual disturbances, postoperative scarring, and inflammation hinder growth of the market. In addition, adverse reactions associated with steroid therapies such as weight gain, loss of bone mineral density, and cataract formation in eyes are expected to limit growth of the market. In contrast, technological improvements in nasal polyps treatment such as availability of key technologies such as nasal endoscopy and computerized tomography for nasal polyps treatment and diagnosis are expected to offer lucrative growth opportunities for players in the nasal polyps treatment market.

The global nasal polyps treatment market is segmented on the basis of type of treatment, route of administration, distribution channel, and region to provide a detailed assessment of the market. By type of treatment, it is bifurcated into corticosteroids, antibiotics, leukotriene inhibitors, and others. Others include antihistamines. By route of administration, it is segmented into oral, nasal, and others. Others include injectable and topical. On the basis of distribution channel, it is categorized into hospitals pharmacies, retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.00

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the nasal polyps treatment market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of nasal polyps treatment used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Type of Treatment

  • Corticosteroids
  • Antibiotics
  • Leukotriene Inhibitors
  • Others

By Route of Administration

  • Oral
  • Nasal
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • AstraZeneca plc
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Intersect ENT Inc.
  • Merck & Co Inc.
  • Novartis International AG
  • OptiNose US
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A
  • Teva Pharmaceutical Industries Ltd.
Frequently Asked Questions about the Global Nasal Polyps Treatment Market

What is the estimated value of the Global Nasal Polyps Treatment Market?

The Global Nasal Polyps Treatment Market was estimated to be valued at $2482.7 million in 2020.

What is the growth rate of the Global Nasal Polyps Treatment Market?

The growth rate of the Global Nasal Polyps Treatment Market is 5.5%, with an estimated value of $4243.9 million by 2030.

What is the forecasted size of the Global Nasal Polyps Treatment Market?

The Global Nasal Polyps Treatment Market is estimated to be worth $4243.9 million by 2030.
Note: Product cover images may vary from those shown

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) along with rise in geriatric population
3.5.1.2. Rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons
3.5.1.3. Huge product pipeline of nasal polyps treatment with growing research activities
3.5.2. Restraints
3.5.2.1. High cost and complications associated with sinus surgeries
3.5.2.2. Adverse reactions associated with steroid therapies
3.5.3. Opportunities
3.5.3.1. Technological improvement in nasal polyps treatment
3.5.4. Impact analysis
3.6. COVID-19 Impact analysis on the nasal polyps treatment market
CHAPTER 4: NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT
4.1. Overview
4.1.1. Market size and forecast
4.2. Corticosteroids
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Antibiotics
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Leukotriene Inhibitors
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Nasal
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: NASAL POLYPS TREATMENT MARKET, DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals Pharmacies
6.2.1. Market size and forecast, by region
6.2.1.1. Market size and forecast for hospital pharmacies, by type of treatment
6.2.2. Market analysis, by country
6.3. Retail Pharmacies
6.3.1. Market size and forecast, by region
6.3.1.1. Market size and forecast for retail pharmacies, by type of treatment
6.3.2. Market analysis, by country
6.4. Online Pharmacies
6.4.1. Market size and forecast
6.4.1.1. Market size and forecast for online pharmacies, by type of treatment
6.4.2. Market analysis, by country
CHAPTER 7: NASAL POLYPS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U. S.
7.2.2.1.1. U. S. nasal polyps treatment market, by type of treatment
7.2.2.1.2. U. S. nasal polyps treatment market, by route of administration
7.2.2.1.3. U. S. nasal polyps treatment market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada nasal polyps treatment market, by type of treatment
7.2.2.2.2. Canada nasal polyps treatment market, by route of administration
7.2.2.2.3. Canada nasal polyps treatment market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico nasal polyps treatment market, by type of treatment
7.2.2.3.2. Mexico nasal polyps treatment market, by route of administration
7.2.2.3.3. Mexico nasal polyps treatment market, by distribution channel
7.2.3. North America market size and forecast, by type of treatment
7.2.4. North America market size and forecast, by route of administration
7.2.5. North America market size and forecast, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany nasal polyps treatment market, by type of treatment
7.3.2.1.2. Germany nasal polyps treatment market, by route of administration
7.3.2.1.3. Germany nasal polyps treatment market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France nasal polyps treatment market, by type of treatment
7.3.2.2.2. France nasal polyps treatment market, by route of administration
7.3.2.2.3. France nasal polyps treatment market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK nasal polyps treatment market, by type of treatment
7.3.2.3.2. UK nasal polyps treatment market, by route of administration
7.3.2.3.3. UK nasal polyps treatment market, by distribution channel
7.3.2.4. Italy
7.3.2.4.1. Italy nasal polyps treatment market, by type of treatment
7.3.2.4.2. Italy nasal polyps treatment market, by route of administration
7.3.2.4.3. Italy nasal polyps treatment market, by distribution channel
7.3.2.5. Spain
7.3.2.5.1. Spain nasal polyps treatment market, by type of treatment
7.3.2.5.2. Spain nasal polyps treatment market, by route of administration
7.3.2.5.3. Spain nasal polyps treatment market, by distribution channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe nasal polyps treatment market, by type of treatment
7.3.2.6.2. Rest of Europe nasal polyps treatment market, by route of administration
7.3.2.6.3. Rest of Europe nasal polyps treatment market, by distribution channel
7.3.3. Europe market size and forecast, by type of treatment
7.3.4. Europe market size and forecast, by route of administration
7.3.5. Europe market size and forecast, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan nasal polyps treatment market, by type of treatment
7.4.2.1.2. Japan nasal polyps treatment market, by route of administration
7.4.2.1.3. Japan nasal polyps treatment market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China nasal polyps treatment market, by type of treatment
7.4.2.2.2. China nasal polyps treatment market, by route of administration
7.4.2.2.3. China nasal polyps treatment market, by distribution channel
7.4.2.3. Australia
7.4.2.3.1. Australia nasal polyps treatment market, by type of treatment
7.4.2.3.2. Australia nasal polyps treatment market, by route of administration
7.4.2.3.3. Australia nasal polyps treatment market, by distribution channel
7.4.2.4. India
7.4.2.4.1. India nasal polyps treatment market, by type of treatment
7.4.2.4.2. India nasal polyps treatment market, by route of administration
7.4.2.4.3. India nasal polyps treatment market, by distribution channel
7.4.2.5. South Korea
7.4.2.5.1. South Korea nasal polyps treatment market, by Type of treatment
7.4.2.5.2. South Korea nasal polyps treatment market, by route of administration
7.4.2.5.3. South Korea nasal polyps treatment market, by distribution channel
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific nasal polyps treatment market, by type of treatment
7.4.2.6.2. Rest of Asia-Pacific nasal polyps treatment market, by route of administration
7.4.2.6.3. Rest of Asia-Pacific nasal polyps treatment market, by distribution channel
7.4.3. Asia-Pacific market size and forecast, by type of treatment
7.4.4. Asia-Pacific market size and forecast, by route of administration
7.4.5. Asia-Pacific market size and forecast, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil nasal polyps treatment market, by type of treatment
7.5.2.1.2. Brazil nasal polyps treatment market, by route of administration
7.5.2.1.3. Brazil nasal polyps treatment market, by distribution channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia nasal polyps treatment market, by type of treatment
7.5.2.2.2. Saudi Arabia nasal polyps treatment market, by route of administration
7.5.2.2.3. Saudi Arabia nasal polyps treatment market, by distribution channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa nasal polyps treatment market, by type of treatment
7.5.2.3.2. South Africa nasal polyps treatment market, by route of administration
7.5.2.3.3. South Africa nasal polyps treatment market, by distribution channel
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA nasal polyps treatment market, by type of treatment
7.5.2.4.2. Rest of LAMEA nasal polyps treatment market, by route of administration
7.5.2.4.3. Rest of LAMEA nasal polyps treatment market, by distribution channel
7.5.3. LAMEA market size and forecast, by type of treatment
7.5.4. LAMEA market size and forecast, by route of administration
7.5.5. LAMEA market size and forecast, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. ASTRAZENECA PLC
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. F. Hoffmann-La Roche AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. GLAXOSMITHKLINE PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Intersect ENT
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. MERCK & CO., INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Novartis International AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Optinose Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Regeneron Pharmaceuticals, Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Sanofi S. A.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
List of Tables
TABLE 01. GLOBAL NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 02. NASAL POLYPS TREATMENT MARKET FOR CORTICOSTEROIDS, BY REGION, 2020-2030($MILLION)
TABLE 03. NASAL POLYPS TREATMENT MARKET FOR ANTIBIOTICS, BY REGION, 2020-2030($MILLION)
TABLE 04. NASAL POLYPS TREATMENT MARKET FOR LEUKOTRIENE INHIBITORS, BY REGION, 2020-2030($MILLION)
TABLE 05. NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
TABLE 06. GLOBAL NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 07. NASAL POLYPS TREATMENT MARKET FOR ORAL, BY REGION, 2020-2030($MILLION)
TABLE 08. NASAL POLYPS TREATMENT MARKET FOR NASAL, BY REGION, 2020-2030($MILLION)
TABLE 09. NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
TABLE 10. GLOBAL NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 11. NASAL POLYPS TREATMENT MARKET FOR HOSPITALS PHARAMCIES, BY REGION, 2020-2030($MILLION)
TABLE 12. NASAL POLYPS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 13. NASAL POLYPS TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 14. NASAL POLYPS TREATMENT MARKET FOR RETAIL PHARMACIES, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 15. NASAL POLYPS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 16. NASAL POLYPS TREATMENT MARKET FOR ONLINE PHARMACIES, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 17. NASAL POLYPS TREATMENT MARKET, BY REGION, 2020-2030($MILLION)
TABLE 18. NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 19. U.S. NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 20. U.S. NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 21. U.S. NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 22. CANADA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 23. CANADA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 24. CANADA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 25. MEXICO NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 26. MEXICO NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 27. MEXICO NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 28. NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 29. NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 30. NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 31. EUROPE NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 32. GERMANY NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 33. GERMANY NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 34. GERMANY NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 35. FRANCE NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 36. FRANCE NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 37. FRANCE NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 38. UK NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 39. UK NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 40. UK NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 41. ITALY NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 42. ITALY NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 43. ITALY NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 44. SPAIN NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 45. SPAIN NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 46. SPAIN NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 47. REST OF EUROPE NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 48. REST OF EUROPE NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 49. REST OF EUROPE NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 50. EUROPE NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 51. EUROPE NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 52. EUROPE NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 53. ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 54. JAPAN NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 55. JAPAN NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 56. JAPAN NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 57. CHINA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 58. CHINA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 59. CHINA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 60. AUSTRALIA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 61. AUSTRALIA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 62. AUSTRALIA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 63. INDIA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 64. INDIA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 65. INDIA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 66. SOUTH KOREA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 67. SOUTH KOREA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 68. SOUTH KOREA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 69. REST OF ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 70. REST OF ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 71. REST OF ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 72. ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 73. ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 74. ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 75. LAMEA NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 76. BRAZIL NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 77. BRAZIL NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 78. BRAZIL NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 79. SAUDI ARABIA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 80. SAUDI ARABIA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 81. SAUDI ARABIA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 82. SOUTH AFRICA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 83. SOUTH AFRICA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 84. SOUTH AFRICA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2030($MILLION)
TABLE 85. REST OF LAMEA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 86. REST OF LAMEA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 87. REST OF LAMEA NASAL POLYPS TREATMENT MARKET, DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 88. LAMEA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 89. LAMEA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 90. LAMEA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 91. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 92. ASTRAZENECA: OPERATING SEGMENTS
TABLE 93. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 94. ROCHE: COMPANY SNAPSHOT
TABLE 95. ROCHE: OPERATING SEGMENTS
TABLE 96. ROCHE: PRODUCT PORTFOLIO
TABLE 97. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98. GSK: COMPANY SNAPSHOT
TABLE 99. GSK: PRODUCT PORTFOLIO
TABLE 100. GSK: PRODUCT PORTFOLIO
TABLE 101. GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. INTERSECTENT: COMPANY SNAPSHOT
TABLE 103. INTERSECTENT: OERATING SEGMENT
TABLE 104. INTERSECTENT: PRODUCT PORTFOLIO
TABLE 105. INTERSECTENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106. MERCK: COMPANY SNAPSHOT
TABLE 107. MERCK: OPERATING SEGMENTS
TABLE 108. MERCK: PRODUCT PORTFOLIO
TABLE 109. NOVARTIS: COMPANY SNAPSHOT
TABLE 110. NOVARTIS: OERATING SEGMENT
TABLE 111. NOVARTIS: PRODUCT PORTFOLIO
TABLE 112. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113. OPTINOSE: COMPANY SNAPSHOT
TABLE 114. OPTINOSE: OPERATING SEGMENTS
TABLE 115. OPTINOSE: PRODUCT PORTFOLIO
TABLE 116. OPTINOSE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. REGENERON: COMPANY SNAPSHOT
TABLE 118. REGENERON: OERATING SEGMENT
TABLE 119. REGENERON: PRODUCT PORTFOLIO
TABLE 120. REGENERON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 121. SANOFI: COMPANY SNAPSHOT
TABLE 122. SANOFI: OERATING SEGMENT
TABLE 123. SANOFI: PRODUCT PORTFOLIO
TABLE 124. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. TEVA: COMPANY SNAPSHOT
TABLE 126. TEVA: OERATING SEGMENT
TABLE 127. TEVA: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. NASAL POLYPS TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. HIGH INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR LEUKOTRIENE INHIBITORS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS NASAL POLYPS TREATMENT MARKET FOR ORAL, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR NASAL, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR HOSPITALS PHARAMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23. ASTRAZENECA: REVENUE, 2018-2020 ($MILLION)
FIGURE 24. ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 25. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 26. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28. GSK: NET SALES, 2018-2020 ($MILLION)
FIGURE 29. GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. GSK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31. INTERSECTENT: NET SALES, 2018-2020 ($MILLION)
FIGURE 32. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 33. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34. MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35. NOVARTIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 36. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38. OPTINOSE: NET SALES, 2018-2020 ($MILLION)
FIGURE 39. REGENERON: NET SALES, 2018-2020 ($MILLION)
FIGURE 40. SANOFI: NET SALES, 2018-2020 ($MILLION)
FIGURE 41. SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42. SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 43. TEVA: NET SALES, 2018-2020 ($MILLION)
FIGURE 44. TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...